AR056138A1 - Procedimiento para la expresion recombinante de un polipeptido - Google Patents
Procedimiento para la expresion recombinante de un polipeptidoInfo
- Publication number
- AR056138A1 AR056138A1 ARP060104562A ARP060104562A AR056138A1 AR 056138 A1 AR056138 A1 AR 056138A1 AR P060104562 A ARP060104562 A AR P060104562A AR P060104562 A ARP060104562 A AR P060104562A AR 056138 A1 AR056138 A1 AR 056138A1
- Authority
- AR
- Argentina
- Prior art keywords
- polypeptide
- nucleic acid
- acid encoding
- procedure
- recombinant expression
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 238000003259 recombinant expression Methods 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 abstract 5
- 102000039446 nucleic acids Human genes 0.000 abstract 5
- 150000007523 nucleic acids Chemical class 0.000 abstract 5
- 239000013613 expression plasmid Substances 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 108091036066 Three prime untranslated region Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000013612 plasmid Substances 0.000 abstract 1
- 230000008488 polyadenylation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se describe un procedimiento para la produccion recombinante de un polipéptido heterologo en una célula huésped eucariota. La célula huésped comprende un plásmido de expresion, por lo cual el plásmido de expresion comprende en una direccion 5' a 3': a) un promotor, b) un ácido nucleico que codifica un primer polipéptido, cuya secuencia de aminoácidos se selecciona a partir de la tabla 1 dependiendo de los dos primeros aminoácidos del segundo polipéptido, c) un ácido nucleico que codifica un segundo polipéptido que comprende un ácido nucleico que codifica un polipéptido heterologo, un ácido nucleico que codifica un agarre, y un ácido nucleico que codifica un fragmento de inmunoglobulina, y d) una region 3' no traducida que comprende una senal de poliadenilacion. Adicionalmente se describen un plásmido y un kit.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05023003 | 2005-10-21 | ||
| EP06010665 | 2006-05-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056138A1 true AR056138A1 (es) | 2007-09-19 |
Family
ID=37734034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060104562A AR056138A1 (es) | 2005-10-21 | 2006-10-19 | Procedimiento para la expresion recombinante de un polipeptido |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7807409B2 (es) |
| EP (1) | EP1941043B1 (es) |
| JP (1) | JP4860702B2 (es) |
| KR (1) | KR101030612B1 (es) |
| CN (1) | CN101292036B (es) |
| AR (1) | AR056138A1 (es) |
| AT (1) | ATE505552T1 (es) |
| AU (1) | AU2006303440B2 (es) |
| BR (1) | BRPI0617688A2 (es) |
| CA (1) | CA2624893C (es) |
| DE (1) | DE602006021335D1 (es) |
| IL (1) | IL189420A (es) |
| TW (1) | TW200732472A (es) |
| WO (1) | WO2007045465A1 (es) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
| EP2051734B1 (en) | 2006-08-18 | 2016-10-05 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| US8974791B2 (en) * | 2007-07-27 | 2015-03-10 | Armagen Technologies, Inc. | Methods and compositions for increasing α-L-iduronidase activity in the CNS |
| EP2214708A4 (en) * | 2007-10-26 | 2011-01-12 | Centocor Ortho Biotech Inc | VECTORS, HOST CELLS, METHODS OF PRODUCTION AND USES |
| EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| DE202010018640U1 (de) | 2009-07-24 | 2019-11-14 | F. Hoffmann-La Roche Ag | Rührersystem |
| EP2485761B1 (en) | 2009-10-09 | 2019-02-27 | Armagen, Inc. | Methods and compositions for increasing iduronate 2-sulfatase activity in the cns |
| EP2493923A1 (en) * | 2009-10-30 | 2012-09-05 | Abbott Laboratories | Sorf constructs and multiple gene expression |
| RS55989B1 (sr) | 2009-11-02 | 2017-09-29 | Univ Washington | Sastavi i postupci terapeutske nukleaze |
| TW201120210A (en) * | 2009-11-05 | 2011-06-16 | Hoffmann La Roche | Glycosylated repeat-motif-molecule conjugates |
| FR2957598B1 (fr) * | 2010-03-17 | 2015-12-04 | Lfb Biotechnologies | Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes |
| WO2011135040A1 (en) | 2010-04-30 | 2011-11-03 | F. Hoffmann-La Roche Ag | Fluorescent antibody fusion protein, its production and use |
| PE20141172A1 (es) | 2011-04-29 | 2014-09-22 | Univ Washington | Composiciones de nucleasa terapeuticas y metodos |
| RU2756106C2 (ru) | 2011-12-22 | 2021-09-28 | Ф. Хоффманн-Ля Рош Аг | Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов |
| SG10201900915WA (en) * | 2011-12-22 | 2019-03-28 | Hoffmann La Roche | Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides |
| WO2013109904A1 (en) * | 2012-01-19 | 2013-07-25 | University Of Miami | Compositions, methods and kits for treatment of cancer and autoimmune diseases |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| CN104854133B (zh) | 2012-10-12 | 2018-10-30 | 新加坡科技研究局 | 用于制备重组抗体治疗剂的最佳重链和轻链信号肽 |
| CN103773770A (zh) * | 2012-10-18 | 2014-05-07 | 高峰 | 一种可分泌的绿色荧光蛋白及其在重组蛋白高产表达细胞株筛选方面的应用 |
| EP2938728B1 (en) | 2012-12-31 | 2020-12-09 | Boehringer Ingelheim International GmbH | Artificial introns |
| WO2014102101A1 (en) * | 2012-12-31 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Novel intron sequences |
| EP2938726B1 (en) | 2012-12-31 | 2017-09-27 | Boehringer Ingelheim International GmbH | Heterologous intron within a signal peptide |
| EP2938725B1 (en) * | 2012-12-31 | 2017-08-23 | Boehringer Ingelheim International GmbH | Heterologous intron within an immunoglobulin domain |
| US10988745B2 (en) | 2013-10-31 | 2021-04-27 | Resolve Therapeutics, Llc | Therapeutic nuclease-albumin fusions and methods |
| EP3620173A1 (en) | 2013-11-21 | 2020-03-11 | Apeiron Biologics AG | Preparations and methods for treating a gd2 positive cancer |
| US9840566B2 (en) * | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| CN104928285A (zh) * | 2014-03-21 | 2015-09-23 | 中国科学院沈阳应用生态研究所 | 载体克隆表达区基因和蛋白分泌型哺乳动物细胞表达载体 |
| EP3680336A1 (en) * | 2014-07-03 | 2020-07-15 | F. Hoffmann-La Roche AG | Polypeptide expression systems |
| ES2876925T3 (es) * | 2014-07-29 | 2021-11-15 | Cellectis | Receptores de antígeno quiméricos específicos para ROR1 (NTRKR1) para inmunoterapia contra el cáncer |
| CA2953450C (en) * | 2014-08-11 | 2023-01-10 | Oliver Popp | Method for increasing the specific production rate of eukaryotic cells |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| CA2979812C (en) * | 2015-03-20 | 2023-08-29 | Universite Paris Descartes | Isolated peptides and fragments thereof from fibrinogen for use as drugs, particularly in skin inflammatory diseases |
| DK3478830T3 (da) | 2016-07-01 | 2024-05-21 | Resolve Therapeutics Llc | Optimerede binucleasefusioner og metoder |
| CA3067247A1 (en) * | 2017-07-11 | 2019-01-17 | Alexion Pharmaceuticals, Inc. | Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof |
| CN111315767B (zh) | 2017-08-22 | 2025-03-18 | 萨纳生物有限责任公司 | 可溶性干扰素受体及其用途 |
| KR20210025522A (ko) * | 2018-06-25 | 2021-03-09 | 유니버시티 오브 워싱톤 | 강력하고 선택적인 인터루킨 모방체의 드 노보 디자인 |
| WO2020041360A1 (en) | 2018-08-21 | 2020-02-27 | Quidel Corporation | Dbpa antibodies and uses thereof |
| CN115851831A (zh) * | 2020-01-17 | 2023-03-28 | 普莱柯生物工程股份有限公司 | 一种高效表达外源蛋白的cho细胞株的构建方法及其应用 |
| TW202229350A (zh) * | 2020-10-14 | 2022-08-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物及方法 |
| CN113024652A (zh) * | 2021-02-25 | 2021-06-25 | 安徽环球基因科技有限公司 | 人髓鞘少突胶质细胞糖蛋白的重组表达及其应用 |
| WO2024197061A2 (en) * | 2023-03-21 | 2024-09-26 | Lung Biotechnology Pbc | Bicistronic constructs for allogeneic gene therapy |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US6458360B1 (en) | 1990-04-25 | 2002-10-01 | The Johns Hopkins University | Soluble complement regulatory molecules |
| AU650085B2 (en) | 1990-11-13 | 1994-06-09 | Immunex Corporation | Bifunctional selectable fusion genes |
| FR2687157B1 (fr) * | 1992-02-11 | 1995-10-06 | Commissariat Energie Atomique | Proteines hybrides complexes, leur procede de preparation, et leurs applications comme agent de diagnostic, comme agent a visee therapeutique ou comme reactif utilisable en imagerie medicale. |
| AU6912294A (en) | 1993-05-12 | 1994-12-12 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| JPH09500783A (ja) | 1993-05-21 | 1997-01-28 | ターゲッティッド ジェネティクス コーポレイション | シトシンデアミナーゼ（ｃｄ）遺伝子に基づく二機能性選択融合遺伝子 |
| KR100937550B1 (ko) | 1996-12-20 | 2010-01-19 | 암젠 인코포레이티드 | Ｏｂ 융합 단백질 조성물과 이 단백질의 제조 방법 |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US20030103984A1 (en) | 1998-05-04 | 2003-06-05 | Heinz Kohler | Fusion proteins of biologically active peptides and antibodies |
| CA2328076C (en) | 1998-04-15 | 2009-10-06 | Lexigen Pharmaceuticals Corporation | Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor |
| WO2000011033A2 (en) * | 1998-08-25 | 2000-03-02 | Lexigen Pharmaceuticals Corp. | Expression and export of angiostatin and endostatin as immunofusins |
| BR0112111A (pt) | 2000-06-29 | 2003-05-06 | Merck Patent Gmbh | Realce de respostas imunes mediadas por proteìna de fusão de anticorpo-citocina por tratamento combinado com agentes de realce de captação de imunocitocina |
| DE10045591A1 (de) | 2000-09-15 | 2002-04-04 | Klaus Pfizenmaier | Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine) |
| WO2003016501A2 (en) * | 2001-08-21 | 2003-02-27 | Thomas Jefferson University | Recombinant antibodies, and compositions and methods for making and using the same |
| US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| WO2003035892A2 (en) | 2001-10-19 | 2003-05-01 | The Scripps Research Institute | Novel methods for introducing molecules into cells and vectors and compositions for use in such methods |
| US7579157B2 (en) | 2003-07-10 | 2009-08-25 | Hoffmann-La Roche Inc. | Antibody selection method against IGF-IR |
-
2006
- 2006-10-19 AR ARP060104562A patent/AR056138A1/es unknown
- 2006-10-19 US US11/583,573 patent/US7807409B2/en active Active
- 2006-10-19 AT AT06806380T patent/ATE505552T1/de active
- 2006-10-19 DE DE602006021335T patent/DE602006021335D1/de active Active
- 2006-10-19 CN CN200680039291.9A patent/CN101292036B/zh active Active
- 2006-10-19 TW TW095138577A patent/TW200732472A/zh unknown
- 2006-10-19 CA CA2624893A patent/CA2624893C/en not_active Expired - Fee Related
- 2006-10-19 BR BRPI0617688-7A patent/BRPI0617688A2/pt not_active Application Discontinuation
- 2006-10-19 EP EP06806380A patent/EP1941043B1/en active Active
- 2006-10-19 AU AU2006303440A patent/AU2006303440B2/en not_active Ceased
- 2006-10-19 KR KR1020087009355A patent/KR101030612B1/ko not_active IP Right Cessation
- 2006-10-19 WO PCT/EP2006/010067 patent/WO2007045465A1/en active Application Filing
- 2006-10-19 JP JP2008533956A patent/JP4860702B2/ja active Active
-
2008
- 2008-02-11 IL IL189420A patent/IL189420A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006303440A1 (en) | 2007-04-26 |
| IL189420A (en) | 2014-06-30 |
| EP1941043A1 (en) | 2008-07-09 |
| US7807409B2 (en) | 2010-10-05 |
| KR101030612B1 (ko) | 2011-04-20 |
| CA2624893A1 (en) | 2007-04-26 |
| BRPI0617688A2 (pt) | 2011-06-07 |
| IL189420A0 (en) | 2008-06-05 |
| JP2009509558A (ja) | 2009-03-12 |
| JP4860702B2 (ja) | 2012-01-25 |
| CN101292036A (zh) | 2008-10-22 |
| CA2624893C (en) | 2015-03-17 |
| AU2006303440B2 (en) | 2011-09-08 |
| US20070117185A1 (en) | 2007-05-24 |
| TW200732472A (en) | 2007-09-01 |
| KR20080049115A (ko) | 2008-06-03 |
| ATE505552T1 (de) | 2011-04-15 |
| CN101292036B (zh) | 2016-04-13 |
| WO2007045465A1 (en) | 2007-04-26 |
| DE602006021335D1 (de) | 2011-05-26 |
| EP1941043B1 (en) | 2011-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056138A1 (es) | Procedimiento para la expresion recombinante de un polipeptido | |
| AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
| AR110502A1 (es) | Polinucleótidos y polipéptidos de adenovirus | |
| CR10591A (es) | Metodo para la produccion de conjugados del factor de crecimiento similar a la insulina-1 y polietilenglicol | |
| ECSP064643A (es) | Proteinas de fusion de glp-1 | |
| FI4176894T3 (fi) | Kimeerisiä tekijä viii -proteiineja ja niiden käyttötarkoituksia | |
| CL2019003410A1 (es) | Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407). | |
| AR049177A1 (es) | Polipeptidos y conjugados de interferon-alfa | |
| ES2102815T3 (es) | Procedimiento para la obtencion de ectodominios nativos, oligomeros, glicosilados de proteinas de membrana virales, su utilizacion, en especial como vacuna contra el vih. | |
| AR071969A1 (es) | Proteasa especifica de prolina identificada en el hongo penicillium chrysogenum | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| ES2531115T3 (es) | Combinaciones de clados de RrgB neumocócicos | |
| AR070491A1 (es) | Variante de enzima lipolitica con estabilidad aumentada y polinucleotidos que la codifican | |
| PE20020857A1 (es) | Proteinas de fusion cuya parte del n-terminal es un derivado de hirudina para la produccion de proteinas recombinantes a traves de la secresion por levaduras | |
| WO2021207517A3 (en) | Modified hr2 peptide inhibitors of coronavirus fusion | |
| BR112023003526A2 (pt) | Proteínas de fusão de coronavírus imunogênicos e métodos relacionados | |
| Gimenes et al. | Isolation and biochemical characterization of a γ-type phospholipase A2 inhibitor from Crotalus durissus collilineatus snake serum | |
| CL2009001249A1 (es) | Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia. | |
| WO2006073976A3 (en) | Compositions, methods, and kits for enhancing protein expression, solubility and isolation | |
| CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
| MX2022002277A (es) | Metodo para incrementar el conteo de linfocitos mediante el uso de proteina de fusion de interleucina 7 (il-7) en tumores. | |
| DK0794255T3 (da) | Fremgangsmåde til spaltning af kimært protein ved anvendelse af processeringsenzym | |
| DK1437401T3 (da) | Oxidoreduktase | |
| ES2143408B1 (es) | Promotor y construcciones para expresion de proteinas recombinantes en hongos filamentosos. | |
| ES2673972T3 (es) | Formas solubles de la glicoproteína G de los virus hendra y nipah |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |